Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2009The OncologistOpen Access

Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMarc PeetersTPTimothy PriceJLJean‐Luc Van Laethem

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Peeters et al. (2009) studied this question.

synapsesocial.com/papers/6a200ed535281a23f90ddbeehttps://doi.org/10.1634/theoncologist.2008-0167
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines2007 · 438 citations
  2. 2<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer2008 · 3,632 citations
  3. 3Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer2005 · 732 citations
  4. 4Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab2007 · 1,134 citations